Oliver Gnehm, lic. iur., MSc (LSE)

Oliver Gnehm, lic. iur., MSc (LSE)

Chairman & Managing Partner
Escritório na Suíça

+41 44 312 20 20
Share via email
oliver.gnehm@actlegal-switzerland.com

Switzerland

Oliver Gnehm, lic. iur., MSc (LSE)

Oliver Gnehm is a trusted legal adviser and accomplished negotiator to leading national and international companies and investors. He advises on venture capital, private equity, M&A and restructuring transactions, as well as corporate and commercial matters. He has particular expertise in deep tech, healthcare and life sciences and has advised on some of Switzerland’s most significant transactions in these sectors. He has been repeatedly recognized as Lawyer of the Year for Healthcare, Life Sciences and Pharma. Clients value his strategic insight, pragmatic approach and commitment to high-value outcomes in complex transactions.

Detalhes

  • Zurich Bar Association
  • SIX Swiss Exchange, accredited expert issuer representative
  • Licensing Executives Society Switzerland
  • Managing Director at BoneSupport Switzerland GmbH
  • Member of the Board of Directors at Leathwaite International AG, TXP Pharma AG and Versantis AG
  • "The information right according to the Swiss data protection law" (Das datenschutzrechtliche Auskunftsrecht - – Nukleus zur prozeduralen Durchsetzung des datenschutzrechtlichen Persönlichkeitsschutzes), Author: Oliver Gnehm, in: Schriftenreihe forum Europarecht (Volume 35), Durchsetzung der Rechte der Betroffenen im Bereich des Datenschutzes, Zurich 2015, pp. 77–106
  • "CO2-Emissions trading as a "lawless" space" (Der CO2-Emissionshandel als "rechtsfreier" Raum), Author: Oliver Gnehm, in: NZZ Gesellschaft & Recht, 24 August 2020
  • Building the Foundation for Successful Negotiations; , Authors: Oliver Gnehm, Fabiola Weilenmann, Thomas Gysin, in: BGPartner Video Publication, 28 September 2022, 10:39 Minutes
  • Interview "How to negotiate M&A and other contracts?" Authors: Oliver Gnehm and Elena Mégevand, in: "Ratgeber Recht & Steuern" supplement to Finanz und Wirtschaft, 4 March 2023
  • Wie verhandeln Schweizer Führungskräfte?, Authors: Uta Herbst, Markus Voeth, Yannick Urbitsch, Sabrina Marx, Michael Oryl, Oliver Gnehm, Elena Mégevand, Barbora Hasler, in: Empirical study, 25 May 2023
  • Vom Umgang mit Garantien in Bauwerkverträgen, Authors: Olivier Bula, Oliver Gnehm, in: Presentation, 14. Zürcher Praktikertag für Baurecht, 21 June 2023
  • Interview "How do Swiss executives negotiate?" Authors: Oliver Gnehm and Elena Mégevand, in: "Ratgeber Recht & Steuern" supplement to Finanz und Wirtschaft, 19 September 2023
  • Interview "BGPartner’s bet on biotech and negotiation - Oliver Gnehm on the Swiss firm’s biotech focus, cross-border dealmaking and why negotiation remains a human advantage in the AI era" in Legalcommunity CH MAG, issue 25, August – September 2026, page 34.
  • Lawyer of the Year Healthcare, Life Sciences, Pharma 2023 and 2024, Legal Community CH
  • Attorney at law (Swiss bar admission, 2005)
  • Chairman and Managing Partner at act legal Switzerland (since 2009, formerly BGPartner Ltd)
  • Attorney at law at a leading Swiss law firm
  • Lecturer at several entrepreneurship schools
  • Cantonal Court of Basel-Landschaft
  • Pfizer Inc., USA
  • UBS, Switzerland
  • London School of Economics and Political Science, MSc in Decision Analysis
  • University of Basel and Fribourg, lic. iur.
  • Harvard Law School, Program on Negotiation
  • German
  • English

awards

Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2024

Ler mais
Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2024
Oliver Gnehm has been named Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2024 – recognising his expertise at act legal Switzerland.
fechar

Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2023

Ler mais
Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2023
Oliver Gnehm has been named Lawyer of the Year for Healthcare, Life Sciences and Pharma by Legal Community Switzerland, 2023 – recognising his expertise at act legal Switzerland.
fechar

news

BGPartner becomes act legal: Swiss business law firm joins act legal
newsEscritório na Suíça01. 10. 2026

BGPartner becomes act legal: Swiss business law firm joins act legal

Ler mais
act legal Switzerland advises OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on Windward Bio's USD 165 million Series B financing
newsEscritório na Suíça28. 05. 2026

act legal Switzerland advises OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on Windward Bio's USD 165 million Series B financing

Ler mais
act legal Switzerland once again recognised as a Best Workplace™ – ranked 2nd in Switzerland
newsEscritório na Suíça22. 05. 2026

act legal Switzerland once again recognised as a Best Workplace™ – ranked 2nd in Switzerland

Ler mais
act legal Switzerland recertified as a Great Place to Work®
newsEscritório na Suíça11. 03. 2026

act legal Switzerland recertified as a Great Place to Work®

Ler mais
Lunch webinar recap: negotiating in crisis – staying in control when it matters most
newsEscritório na Suíça19. 06. 2025

Lunch webinar recap: negotiating in crisis – staying in control when it matters most

Ler mais
act legal Switzerland advises Novo Holdings and LifeArc Ventures on the USD 130 million Series B financing of GlycoEra Ltd
newsEscritório na Suíça28. 05. 2025

act legal Switzerland advises Novo Holdings and LifeArc Ventures on the USD 130 million Series B financing of GlycoEra Ltd

Ler mais
act legal Switzerland again recognised as one of Switzerland's top law firms
newsEscritório na Suíça30. 04. 2025

act legal Switzerland again recognised as one of Switzerland's top law firms

Ler mais
act legal Switzerland advises on a USD 1.1 billion transaction
newsEscritório na Suíça18. 03. 2025

act legal Switzerland advises on a USD 1.1 billion transaction

Ler mais

track-records

Advising a Swiss-based internationally active manufacturer on matters relating to a letter of credit and export credit insurance.
track-record

Advising a Swiss-based internationally active manufacturer on matters relating to a letter of credit and export credit insurance.

Advising Germany's GOLDBECK Holding GmbH on the acquisition of 100 per cent of A. Boss & Co AG, the largest acquisition in the DACH greeting card segment to date.
track-record

Advising Germany's GOLDBECK Holding GmbH on the acquisition of 100 per cent of A. Boss & Co AG, the largest acquisition in the DACH greeting card segment to date.

Advising SIX-listed Lalique Group SA on its 2024 Annual General Meeting, including the shareholder vote on the delisting of its shares.
track-record

Advising SIX-listed Lalique Group SA on its 2024 Annual General Meeting, including the shareholder vote on the delisting of its shares.

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.
track-record

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.

Advising lead investor Novo Holdings and new investor LifeArc Ventures on the oversubscribed USD 130 million Series B financing of GlycoEra Ltd.
track-record

Advising lead investor Novo Holdings and new investor LifeArc Ventures on the oversubscribed USD 130 million Series B financing of GlycoEra Ltd.

Advising OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on all Swiss law aspects of the USD 165 million Series B financing of Windward Bio Group AG, including the related negotiations.
track-record

Advising OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on all Swiss law aspects of the USD 165 million Series B financing of Windward Bio Group AG, including the related negotiations.

Advising Araris Biotech AG on the sale of all of its shares to Taiho Pharmaceutical Co., Ltd. in a transaction worth up to USD 1.1 billion.
track-record

Advising Araris Biotech AG on the sale of all of its shares to Taiho Pharmaceutical Co., Ltd. in a transaction worth up to USD 1.1 billion.

Advising co-lead investors Forbion and Jeito Capital on the oversubscribed Series B financing of Noema Pharma Ltd of approximately USD 112 million.
track-record

Advising co-lead investors Forbion and Jeito Capital on the oversubscribed Series B financing of Noema Pharma Ltd of approximately USD 112 million.

Advising Swixx Biopharma AG on a EUR 200 million syndicated credit facility with UBS, Credit Suisse, Citibank Europe and BNP Paribas (Suisse) SA, including leading the negotiations.
track-record

Advising Swixx Biopharma AG on a EUR 200 million syndicated credit facility with UBS, Credit Suisse, Citibank Europe and BNP Paribas (Suisse) SA, including leading the negotiations.

Advising Araris Biotech Ltd on a strategic investment by Samsung Ventures, including leading the negotiations.
track-record

Advising Araris Biotech Ltd on a strategic investment by Samsung Ventures, including leading the negotiations.

Advising Memo Therapeutics Ltd on its CHF 25 million Series C financing round led by Pureos Bioventures.
track-record

Advising Memo Therapeutics Ltd on its CHF 25 million Series C financing round led by Pureos Bioventures.

Advising Memo Therapeutics Ltd on the CHF 20 million extension of its Series C financing, bringing the round to CHF 45 million.
track-record

Advising Memo Therapeutics Ltd on the CHF 20 million extension of its Series C financing, bringing the round to CHF 45 million.

Advising lead investor Novo Holdings together with EQT Life Sciences, OrbiMed and SR One on the oversubscribed USD 100 million Series C financing of Asceneuron SA.
track-record

Advising lead investor Novo Holdings together with EQT Life Sciences, OrbiMed and SR One on the oversubscribed USD 100 million Series C financing of Asceneuron SA.

Advising OrbiMed, Novo Holdings and Catalio Capital on the oversubscribed USD 181.4 million Series D financing of Alentis Therapeutics AG.
track-record

Advising OrbiMed, Novo Holdings and Catalio Capital on the oversubscribed USD 181.4 million Series D financing of Alentis Therapeutics AG.

Advising EQT, Forbion and Jeito on the extension of the Series B financing of Noema Pharma Ltd to USD 147 million.
track-record

Advising EQT, Forbion and Jeito on the extension of the Series B financing of Noema Pharma Ltd to USD 147 million.

Advising OrbiMed and Novo Holdings on the USD 200 million Series A financing of Windward Bio Group AG.
track-record

Advising OrbiMed and Novo Holdings on the USD 200 million Series A financing of Windward Bio Group AG.

Advising Forbion, Novo Holdings and HBM Healthcare Investments on the Series C top-up financing of Numab Therapeutics Ltd, raising the round to CHF 180 million.
track-record

Advising Forbion, Novo Holdings and HBM Healthcare Investments on the Series C top-up financing of Numab Therapeutics Ltd, raising the round to CHF 180 million.

Advising the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund (EQT) and SR One on the two largest Swiss financing rounds of 2024, as recorded in the Swiss Venture Capital Report 2025.
track-record

Advising the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund (EQT) and SR One on the two largest Swiss financing rounds of 2024, as recorded in the Swiss Venture Capital Report 2025.

Oliver Gnehm, lic. iur., MSc (LSE)

Share via email

act legal BGPartner Ltd
General-Guisan-Quai 38
CH-8027 Zurich
Switzerland

Voltar à visão geral de Profissionais

Ir para
os escritórios

Ir para os escritórios